Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Off-the-Shelf, Third-Party Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Sumithira Vasu, MDMBBS, Bhavana Bhatnagar, DO, James S. Blachly, MD, Nicole Szuminski, BS, Lynn O'Donnell, PhD, Dean Anthony Lee, MD PhD

Blood (2020) 136 (Supplement 1): 44.

https://doi.org/10.1182/blood-2020-139170

Published: 2020

Journal Articles

Psychological Distress in Young Adults with Acute Myeloid Leukemia Undergoing Induction Chemotherapy

Bethany Lockwood, MD, Areej El-Jawahri, MD, Alison R. Walker, MD, Deborah Russell, FNP-BC,ACHPN, Jillian Gustin, MD, Sarah Ehrman, MD, Seuli Bose-Brill, MD, Maryam Lustberg, MD, Bhavana Bhatnagar, DO

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-140589

Published: 2020

Journal Articles

Post-Traumatic Stress Disorder (PTSD) Symptoms in Patients with Acute Myeloid Leukemia (AML)

Hermioni L. Amonoo, MD, Areej El-Jawahri, MD, Thomas W. LeBlanc, MDMA,MS, Alison R. Kavanaugh, NP, Jason A. Webb, MD, Lara Traeger, PhD, Annemarie D. Jagielo, BA, Dagny M. Vaughn, MS, Madeleine Elyze, BA, Regina M. Longley, BA, Amir T. Fathi, Gabriela S. Hobbs, MD, Andrew M. Brunner, Nina R. O'Connor, MD, Selina M. Luger, MD FRCPC, Jillian Gustin, MD, Bhavana Bhatnagar, DO, Nora K. Horick, MS

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-133857

Published: 2020

Journal Articles

Poor Treatment Outcomes of Young (<60 Years) African American Patients (Pts) Diagnosed with Acute Myeloid Leukemia (AML) (Alliance)

Blood (2020) 136 (Supplement 1): 5–7.

https://doi.org/10.1182/blood-2020-140999

Published: 2020

Journal Articles

Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation

Jessica K. Altman, MD, Selina M. Luger, MD FRCPC, Olga Frankfurt, MD, Tsila Zuckerman, MD, Jamie L. Koprivnikar, MD, Vamsi Kota, MD, Ashkan Emadi, MD, PhD, Bhavana Bhatnagar, DO, Dale L. Bixby, MD, Micah M. Burch, MD, Ofir Wolach, MD, Itai Levi, MD, Anna Gourevitch, MD, Ron Ram, MD, Liat Flaishon, PhD MD, Shoshi Tessler, PhD, Stela Gengrinovitch, PhD, Ruth Ben Yakar, PhD, Jacob M. Rowe, MB, BS

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-139136

Published: 2020

Journal Articles

Multi-Site Randomized Trial of Integrated Palliative and Oncology Care for Patients with Acute Myeloid Leukemia (AML)

Areej El-Jawahri, MD, Thomas W. Leblanc, Alison R. Kavanaugh, NP, Jason A. Webb, MD, Vicki Jackson, MD, Toby Campbell, MD, Nina R. O'Connor, MD, Selina M. Luger, MD FRCPC, Ellin Gafford, MD, Jillian Gustin, MD, Bhavana Bhatnagar, DO, Amir T. Fathi, MD, Gabriela S. Hobbs, MD, Showly Nicholson, BS, Debra Davis, Jennifer S. Temel

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-138883

Published: 2020

Journal Articles

Factors Associated with High Healthcare Utilization at the End-of-Life (EOL) for Patients with Acute Myeloid Leukemia

Dagny M. Vaughn, MS, P. Connor Johnson, MD, Annemarie D. Jagielo, BA, Matthew J. Reynolds, BA, Alison R. Kavanaugh, NP, Jason A. Webb, MD, Amir T. Fathi, MD, Gabriela S. Hobbs, MD, Andrew M. Brunner, MD, Nina R. O'Connor, MD, Selina M. Luger, MD FRCPC, Bhavana Bhatnagar, DO, Thomas W. LeBlanc, MDMA,MS, Areej El-Jawahri, MD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-139777

Published: 2020

Journal Articles

Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome

Sangmin Lee, MD, Bhavana Bhatnagar, DO, Sanjay R Mohan, MD MSCI, William T. Senapedis, Jr., Erkan Baloglu, PhD, Hongwei Wang, MD, Jatin J. Shah, MD, Sharon Shacham, PhD MBA, Michael G. Kauffman, MD PhD

Blood (2019) 134 (Supplement_1): 2997.

https://doi.org/10.1182/blood-2019-124136

Published: 2019

Journal Articles

ROR1 Targeted Immunoliposomal Delivery of OSU-2S Show Selective Cytotoxicity in t(1;19) Translocated B-ALL

Swagata Goswami, MSc, Chi-Ling Chiang, PhD, Kevan Zapolnik, BS, Zhiliang Xie, James L. Lee, PhD, Sivasubramanian Baskar, Christoph Rader, PhD, John C. Byrd, MD, Mitch A. Phelps, PhD, Bhavana Bhatnagar, DO, Natarajan Muthusamy, DVM,PhD

Blood (2019) 134 (Supplement_1): 3798.

https://doi.org/10.1182/blood-2019-128828

Published: 2019

Journal Articles

A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

Daniel J. DeAngelo, MD PhD, Harry P. Erba, MD PhD, Brian A Jonas, MD PhD, Michael E O'Dwyer, MD, Paula Marlton, MBBS (Hons), FRACP, FRCPA, Gerwin Huls, MD PhD, Jane L. Liesveld, MD, Brenda Cooper, MD, Bhavana Bhatnagar, DO, Geoffrey L. Uy, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Michael B. Armstrong, MD PhD, William E. Fogler, PhD, Mary M Chen, MD PhD, John L. Magnani, PhD, Helen M Thackray, MD, Eric J. Feldman, MD, Anjali S. Advani, MD, Pamela S. Becker, MD PhD

Blood (2019) 134 (Supplement_1): 2650.

https://doi.org/10.1182/blood-2019-123816

Published: 2019

Journal Articles

NPM1 mutations Using Deep Amplicon Sequencing and Broad Next Generation Sequencing at the Time of Complete Remission Is Informative to Predicting Risk of Relapse Following Intensive Chemotherapy

Bhavana Bhatnagar, DO, Shelley Orwick, BS, Nyla A. Heerema, PhD, Alison R. Walker, MD, Alice S. Mims, MD, James S. Blachly, MD, Karilyn Larkin, MD, Nicole Grieselhuber, MD PhD, Gregory K. Behbehani, MD PhD, Apollinaire Ngankeu, Charles Thomas Gregory, BS, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 1329.

https://doi.org/10.1182/blood-2019-130856

Published: 2019

Journal Articles

A Precision Medicine Heirarchical Classification Developed Using Variant Allele Frequency (VAF) for Treatment of Older Patients (Pts) with Acute Myeloid Leukemia (AML): Alliance Clinical Trials in Oncology (Alliance) Historical Patient Control

Blood (2018) 132 (Supplement 1): 1489.

https://doi.org/10.1182/blood-2018-99-116717

Published: 2018

Journal Articles

Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study

Farhad Ravandi, MD, Asad Bashey, MD PhD, James M. Foran, MD, Wendy Stock, MD, Raya Mawad, MD, William Blum, MD, M. Wayne Saville, MD, Chelsea M. Johnson, BSN, K. Gary J. Vanasse, MD, Thomas Ly, PhD, Hagop M. Kantarjian, MD, Bhavana Bhatnagar, DO, Koichi Takahashi, MD, Alice S. Mims, MD

Blood (2018) 132 (Supplement 1): 763.

https://doi.org/10.1182/blood-2018-99-119786

Published: 2018

Journal Articles

Impact of Cytokine Release Syndrome on Outcomes after T-Cell Replete Peripheral Blood Haploidentical Donor Transplantation

Blood (2018) 132 (Supplement 1): 3357.

https://doi.org/10.1182/blood-2018-99-114100

Published: 2018

Journal Articles

Response Rates, Non-Relapse Mortality, and Financial Implications of Transplant-Associated Thrombotic Microangiopathy Treated with Eculizumab

Blood (2017) 130 (Supplement 1): 1932.

https://doi.org/10.1182/blood.V130.Suppl_1.1932.1932

Published: 2017

Journal Articles

Acute Myeloid Leukemia (AML) Patients with an Isolated Trisomy Display Increased Frequency of Spliceosome Mutations

Bhavana Bhatnagar, DO, Ann-Kathrin Eisfeld, MD, Krzysztof Mrózek, MDPhD, Jessica Kohlschmidt, PhD, Deedra Nicolet, MS, Jonathan E. Kolitz, MD, Bayard L. Powell, MD, John C. Byrd, MD, Clara D. Bloomfield, MD

Blood (2017) 130 (Supplement 1): 2691.

https://doi.org/10.1182/blood.V130.Suppl_1.2691.2691

Published: 2017

Journal Articles

The Novel BET Inhibitor PLX51107 Has In Vitro and In Vivo Activity Against Acute Myeloid Leukemia

Nicole R. Grieselhuber, MD PhD, Shaneice R. Mitchell, BS, Shelley Orwick, BS, Bonnie K. Harrington, DVM, Virginia M. Goettl, DVM, PhD, Alison R. Walker, MD MPH, Bhavana Bhatnagar, DO, Alice S. Mims, MD MSCR, Rebecca B. Klisovic, MD, Sumithra Vasu, MBBS, William Blum, MD, James S. Blachly, MD, David M. Lucas, PhD, Ramiro Garzon, MD, Rosa Lapalombella, PhD, John C. Byrd, MD

Blood (2016) 128 (22): 3941.

https://doi.org/10.1182/blood.V128.22.3941.3941

Published: 2016

Journal Articles

Interim Results of a Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia

Alison R. Walker, MD MPH, Bhavana Bhatnagar, DO, A. Mario Q. Marcondes, MD, Julie DiPaolo, PhD, Sumithra Vasu, MBBS, Alice S. Mims, MD MSCR, Rebecca B. Klisovic, MD, Katherine J. Walsh, MD, Renee Canning, RN, Gregory K. Behbehani, MD PhD, Ramiro Garzon, MD, James S. Blachly, MD, Amy J. Johnson, PhD, Esteban Abella-Dominicis, John C. Byrd, MD, William Blum, MD

Blood (2016) 128 (22): 2831.

https://doi.org/10.1182/blood.V128.22.2831.2831

Published: 2016

Journal Articles

A Phase 1 Clinical Trial of Selinexor in Combination with Decitabine in Patients with Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia

Bhavana Bhatnagar, DO, Rebecca B. Klisovic, MD, Alison R. Walker, MD MPH, Sumithra Vasu, MBBS, Alice S. Mims, MD MSCR, Katherine J. Walsh, MD, Gregory K. Behbehani, MD PhD, James S. Blachly, MD, Molly Vittorio, Qiuhong Zhao, Amy S. Ruppert, MAS, Shelley Orwick, BS, Parvathi Ranganathan, PhD, John C. Byrd, MD, William Blum, MD, Ramiro Garzon, MD

Blood (2016) 128 (22): 1651.

https://doi.org/10.1182/blood.V128.22.1651.1651

Published: 2016

Journal Articles

Lack of Response of Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) to Decitabine After Failure of Azacitidine

Bhavana Bhatnagar, DO, Dan P. Zandberg, M.D., Emily J. Vannorsdall, M.D., Alison P. Duffy, Pharm.D., Michael L. Tidwell, C.R.N.P., Yi Ning, Qing Chen, M.D., Maria R. Baer, M.D.

Blood (2012) 120 (21): 3858.

https://doi.org/10.1182/blood.V120.21.3858.3858

Published: 2012

NARROW

A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Off-the-Shelf, Third-Party Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Psychological Distress in Young Adults with Acute Myeloid Leukemia Undergoing Induction Chemotherapy

Post-Traumatic Stress Disorder (PTSD) Symptoms in Patients with Acute Myeloid Leukemia (AML)

Poor Treatment Outcomes of Young (<60 Years) African American Patients (Pts) Diagnosed with Acute Myeloid Leukemia (AML) (Alliance)

Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation

Multi-Site Randomized Trial of Integrated Palliative and Oncology Care for Patients with Acute Myeloid Leukemia (AML)

Factors Associated with High Healthcare Utilization at the End-of-Life (EOL) for Patients with Acute Myeloid Leukemia

Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome

ROR1 Targeted Immunoliposomal Delivery of OSU-2S Show Selective Cytotoxicity in t(1;19) Translocated B-ALL

A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

NPM1 mutations Using Deep Amplicon Sequencing and Broad Next Generation Sequencing at the Time of Complete Remission Is Informative to Predicting Risk of Relapse Following Intensive Chemotherapy

A Precision Medicine Heirarchical Classification Developed Using Variant Allele Frequency (VAF) for Treatment of Older Patients (Pts) with Acute Myeloid Leukemia (AML): Alliance Clinical Trials in Oncology (Alliance) Historical Patient Control

Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study

Impact of Cytokine Release Syndrome on Outcomes after T-Cell Replete Peripheral Blood Haploidentical Donor Transplantation

Response Rates, Non-Relapse Mortality, and Financial Implications of Transplant-Associated Thrombotic Microangiopathy Treated with Eculizumab

Acute Myeloid Leukemia (AML) Patients with an Isolated Trisomy Display Increased Frequency of Spliceosome Mutations

The Novel BET Inhibitor PLX51107 Has In Vitro and In Vivo Activity Against Acute Myeloid Leukemia

Interim Results of a Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia

A Phase 1 Clinical Trial of Selinexor in Combination with Decitabine in Patients with Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia

Lack of Response of Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) to Decitabine After Failure of Azacitidine

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only